4th Annual Meeting, American Society of Gene Therapy

美国基因治疗学会第四届年会

基本信息

项目摘要

DESCRIPTION (provided by applicant): For gene therapy it has been the best of times and the worst of times. Rarely a technology in medicine has undergone such scrutiny, partly because of the broad promise that this field holds. The tragedy of young Gelsinger is partly offset by the successes in children with SCID (severe combined immunodeficiency) who are now enjoying a normal childhood. Additionally, there are promising and encouraging results on the treatment of hemophilia and certain types of cancer. There are also exciting new results in several pre-clinical models. The American Society of Gene Therapy (ASGT) will hold its 4th annual meeting in Seattle, Washington from May 31-June 3, 2001, to discuss the latest and exciting results in the field of gene therapy. The three and a half day meeting will include 3 keynote addresses, 9-10 symposia (4 speakers/symposia), presidential symposia, special symposia on future biology, 20 colloquia (selected from submitted abstracts), 10-15 workshops (6-8 speakers/workshop), 20 education seminars, 20 meet-the-professor sessions, 3 days of poster viewing, high school student/teacher outreach program, public education, and corporate symposia. The general areas covered in the meeting will be gene therapy approaches to cardiovascular disease, cancer, genetic diseases, infectious diseases, musculo-skeletal disorders, neuronal disorders, and hematopoiesis. The workshops are designed to discuss the improvements in delivery systems, production of vectors, novel vector systems, and specific diseases. The education program is to acquaint the attendees of general areas of gene therapy to broaden their horizons. The "meet-the-professor" sessions are designed to promote interaction among young investigators and faculty members. Young scientists working in the field of gene therapy will have opportunities to present their work in colloquia and at the poster sessions. Based on the 3rd ASGT meeting and a recent increase in membership, we expect nearly 2,500-3,000 participants. We have planned a program where 10-15 percent of the participants will have an opportunity to make oral presentations. Because of the breadth and wide scope of gene therapy, we seek "cross-institutional support" for the meeting from the NIH, including, but not limited to NHLBI, OD, NCI, NEI, NHGRJ, NIA, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIGMS, NIMH, and NINDS. Emphasis on education and extensive participation of young practitioners in the field, give the annual ASGT meeting a unique niche. Indeed, in just four years, the annual ASGT meeting has become "the premier scientific meeting in gene therapy."
描述(由申请人提供):对于基因治疗,它是最好的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

INDER Mohan VERMA其他文献

INDER Mohan VERMA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('INDER Mohan VERMA', 18)}}的其他基金

Molecular Mechanisms and Therapeutic Approaches to Malignant Gliomas
恶性胶质瘤的分子机制和治疗方法
  • 批准号:
    9187795
  • 财政年份:
    2015
  • 资助金额:
    $ 3.25万
  • 项目类别:
MULTISCALE CHARACTERIZATION OF VIRAL VECTOR-INDUCED GLIOBLASTOMAS
病毒载体诱导的胶质母细胞瘤的多尺度表征
  • 批准号:
    8361918
  • 财政年份:
    2011
  • 资助金额:
    $ 3.25万
  • 项目类别:
MULTISCALE CHARACTERIZATION OF VIRAL VECTOR-INDUCED GLIOBLASTOMAS
病毒载体诱导的胶质母细胞瘤的多尺度表征
  • 批准号:
    8169618
  • 财政年份:
    2010
  • 资助金额:
    $ 3.25万
  • 项目类别:
Mouse Models and Cancer Stem Cells
小鼠模型和癌症干细胞
  • 批准号:
    7944578
  • 财政年份:
    2009
  • 资助金额:
    $ 3.25万
  • 项目类别:
MULTISCALE CHARACTERIZATION OF VIRAL VECTOR-INDUCED GLIOBLASTOMAS
病毒载体诱导的胶质母细胞瘤的多尺度表征
  • 批准号:
    7957628
  • 财政年份:
    2009
  • 资助金额:
    $ 3.25万
  • 项目类别:
MULTISCALE CHARACTERIZATION OF VIRAL VECTOR-INDUCED GLIOBLASTOMAS
病毒载体诱导的胶质母细胞瘤的多尺度表征
  • 批准号:
    7722462
  • 财政年份:
    2008
  • 资助金额:
    $ 3.25万
  • 项目类别:
IDENTIFICATION OF IKK SIGNALING TARGETS
IKK 信号目标的识别
  • 批准号:
    7420667
  • 财政年份:
    2006
  • 资助金额:
    $ 3.25万
  • 项目类别:
Program Leader
项目负责人
  • 批准号:
    6990342
  • 财政年份:
    2004
  • 资助金额:
    $ 3.25万
  • 项目类别:
IDENTIFICATION OF IKK SIGNALING TARGETS
IKK 信号目标的识别
  • 批准号:
    6979537
  • 财政年份:
    2004
  • 资助金额:
    $ 3.25万
  • 项目类别:
NHF Fifth Workshop on Gene Therapies for Hemophilia
NHF 第五届血友病基因治疗研讨会
  • 批准号:
    6507846
  • 财政年份:
    2002
  • 资助金额:
    $ 3.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了